The Molecular and Cellular Basis of Hutchinson-Gilford Progeria Syndrome and Potential Treatments.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing molecular mechanisms and therapeutic concepts without original human data or systematic review methods.
PubMed 36980874 · doi:10.3390/genes14030602
What was done
This is a narrative review detailing the molecular and cellular pathogenesis of Hutchinson-Gilford progeria syndrome (HGPS), focusing on de novo LMNA gene point mutations that generate the mutant protein progerin. It describes downstream cellular phenotypes including nuclear structure defects, impaired DNA damage response and repair, accelerated telomere attrition, and epigenetic changes, alongside emerging therapeutic strategies.
What was found
No quantitative findings or numeric effect sizes are reported in the abstract. The abstract qualitatively notes that progerin operates in a dominant-negative manner, that HGPS shares cellular features with normal aging while diverging clinically with accelerated connective tissue phenotypes, and that recently developed treatments provide cellular-level effects, symptomatic improvement, and increased lifespan.
Why it matters
The paper summarizes the mechanistic understanding of how LMNA mutations and progerin induce accelerated aging phenotypes, highlighting potential molecular targets for disease-modifying therapies.
Limits
The paper is a non-systematic narrative review providing no primary clinical data, quantitative effect sizes, or methodology for literature selection. Specific treatment regimens and precise clinical outcome metrics are not detailed in the abstract.
Cited by
- supports Children with progeria age prematurely to resemble 80- or 90-year-olds by the age of 7 or 8 due to a single point mutation.